Aging

Metabolic Syndrome as a Determinant of Bidirectional Transitions Between Frailty States: Evidence From the Whitehall II Study.

BACKGROUND

Understanding interactions between geriatric syndromes is central for promoting healthy aging. Frailty is among the most relevant, as it predicts disability, falls, hospitalization and mortality. In addition, emerging evidence also indicates that metabolic factors play a key role in the...

🗓️ 2026-07-08
📰 Publication: Journal Of Cachexia Sarcopenia And Muscle
Read MoreMetabolic Syndrome as a Determinant of Bidirectional Transitions Between Frailty States: Evidence From the Whitehall II Study.

Assessing the relationships between frailty, sarcopenia and Alzheimer's disease biomarkers: a scoping review.

INTRODUCTION

While both frailty and sarcopenia have been linked with the Alzheimer's disease (AD) clinical phenotype, their association with AD pathophysiology is unclear. This review aimed to identify current evidence of relationships between frailty, sarcopenia and AD biomarkers.

METHODS

Four databases (Ovid MEDLINE,...

🗓️ 2026-07-08
📰 Publication: Ageing Research Reviews
Read MoreAssessing the relationships between frailty, sarcopenia and Alzheimer's disease biomarkers: a scoping review.

Frailty phenotype transitions and functional improvements during a supervised exercise trial in older people with HIV: results from the HEALTH Trial.

BACKGROUND

Frailty and sarcopenia contribute to functional decline in older people with HIV (PWH), yet intervention data remain limited. We evaluated changes in frailty phenotype status, sarcopenia-related outcomes and functional performance during a supervised exercise trial and assessed associations between baseline...

🗓️ 2026-07-06
📰 Publication: Age And Ageing
Read MoreFrailty phenotype transitions and functional improvements during a supervised exercise trial in older people with HIV: results from the HEALTH Trial.

Associations of length of stay with sarcopenia parameters in geriatric patients: age and sex differences in the oldest old.

BACKGROUND

Hospital-associated deconditioning is a contributor to secondary sarcopenia, which may be driven by prolonged hospital length of stay (LoS). This study investigated the bidirectional association of LoS and sarcopenia indices (lean soft tissue, muscle strength, physical function) in older inpatients,...

🗓️ 2026-06-25
📰 Publication: Aging Clinical And Experimental Research
Read MoreAssociations of length of stay with sarcopenia parameters in geriatric patients: age and sex differences in the oldest old.

3,3'-Diindolylmethane ameliorates muscle atrophy by modulating mitochondrial function and calcium homeostasis.

BACKGROUND

Sarcopenia is a chronic degenerative condition characterized by the progressive loss of muscle mass and function. Current therapeutic strategies exhibit limited therapeutic efficacy and present substantial challenges in ensuring sustained patient compliance. Although mitochondrial dysfunction is a confirmed biomarker of...

🗓️ 2026-06-18
📰 Publication: Phytomedicine
Read More3,3'-Diindolylmethane ameliorates muscle atrophy by modulating mitochondrial function and calcium homeostasis.

RNF10 Attenuates Age-Related Muscle Atrophy by Promoting p53 Degradation and Alleviating Oxidative Stress.

Evidence identifies proteostasis imbalance and oxidative stress serve as fundamental pathological hallmarks of muscular atrophy, yet ring finger protein 10 (RNF10), a novel E3 ubiquitin ligase, in age-related muscular atrophy remains poorly characterized. Employing a natural aging mouse model and...

🗓️ 2026-06-18
📰 Publication: Free Radical Biology And Medicine
Read MoreRNF10 Attenuates Age-Related Muscle Atrophy by Promoting p53 Degradation and Alleviating Oxidative Stress.

Muscle Ageing and Sarcopenia Study (MASS) Lifecourse: a valuable resource for understanding skeletal muscle ageing.

Advances in our understanding of the biology of skeletal muscle ageing are being made at pace, with great potential for these findings to inform the identification of novel treatments for sarcopenia. However, translation of findings from animal models to humans...

🗓️ 2026-06-15
Read MoreMuscle Ageing and Sarcopenia Study (MASS) Lifecourse: a valuable resource for understanding skeletal muscle ageing.

Muscle-Adipose Aging Dynamics and Inflammaging Patterns Across Ethnically Diverse Populations: Exploring Potential Roles of Lipolysis.

BACKGROUND

Muscle-adipose aging reflects interactions between body composition changes and chronic inflammatory processes, but age-related patterns in these measures across ethnically diverse populations remain incompletely described. Understanding population-specific patterns is crucial for developing tailored prevention and intervention strategies. We aimed to...

🗓️ 2026-06-04
📰 Publication: Journal Of Cachexia Sarcopenia And Muscle
Read MoreMuscle-Adipose Aging Dynamics and Inflammaging Patterns Across Ethnically Diverse Populations: Exploring Potential Roles of Lipolysis.

Exploring the role of parathyroid hormone in sarcopenia: A review.

PURPOSE OF REVIEW

Sarcopenia is a progressive, multifactorial geriatric syndrome linked to increased risk of falls, fractures, disability, frailty, and all-cause mortality. The pathophysiology of this complex syndrome remains unclear. Emerging evidence suggests that chronically elevated parathyroid hormone (PTH) concentration may...

🗓️ 2026-05-27
Read MoreExploring the role of parathyroid hormone in sarcopenia: A review.

The Gut-Muscle Axis in Sarcopenia: Mechanisms, Evidence Gaps and Translational Challenges.

Sarcopenia is an age-related skeletal muscle disorder characterized by reduced muscle mass, strength, and physical performance, as well as increased risk of disability, hospitalization, and mortality. Emerging evidence suggests that gut microbiota alterations may contribute to muscle decline via a...

🗓️ 2026-05-27
Read MoreThe Gut-Muscle Axis in Sarcopenia: Mechanisms, Evidence Gaps and Translational Challenges.

Food-derived bioactive peptides in gut-muscle Axis regulation: Potential and challenges from microbiota homeostasis to muscle metabolism remodeling.

The global population is aging at an accelerating pace, and sarcopenia has emerged as a central challenge to elderly health. Food-derived bioactive peptides, as natural functional compounds, can interact significantly with the gut microbiota, thereby indirectly influencing muscle metabolism and...

🗓️ 2026-05-22
📰 Publication: Food Research International
Read MoreFood-derived bioactive peptides in gut-muscle Axis regulation: Potential and challenges from microbiota homeostasis to muscle metabolism remodeling.

Why Osteosarcopenia Matters: Clinical and Investigative Implications.

BACKGROUND

Osteosarcopenia, the combination of osteoporosis and sarcopenia, is a geriatric syndrome linked to functional decline, falls, and fragility fractures. The interaction among bone, muscle, and their shared pathophysiology is driven by mechanical, metabolic, and hormonal factors. With global population aging...

🗓️ 2026-05-15
📰 Publication: European Journal Of Clinical Investigation
Read MoreWhy Osteosarcopenia Matters: Clinical and Investigative Implications.

Control of muscle mass during growth and aging: Clinical targets and pathways.

Muscle mass is a strong indicator of overall health in older adults. In healthy individuals, an adequate muscle mass is maintained through a balance between anabolic pathways, such as the mTOR pathway (mammalian target of rapamycin), and catabolic pathways, including...

🗓️ 2026-05-14
📰 Publication: Best Practice & Research Clinical Endocrinology & Metabolism
Read MoreControl of muscle mass during growth and aging: Clinical targets and pathways.

The diagnostic accuracy of blood biomarkers for sarcopenia, sarcopenic obesity, and osteosarcopenia: a meta-analysis.

BACKGROUND AND AIMS

Sarcopenia is the accelerated loss of skeletal muscle mass and function associated with ageing. Sarcopenia screening consists of body composition imaging and physical function tests; however, these tests can be burdensome and inconsistent. This review aimed to synthesise...

🗓️ 2026-05-11
📰 Publication: Archives Of Gerontology And Geriatrics
Read MoreThe diagnostic accuracy of blood biomarkers for sarcopenia, sarcopenic obesity, and osteosarcopenia: a meta-analysis.

Elevated Circulating Ceramides 18:0 and 24:1 as a Risk Factor for Sarcopenia: In Vitro, Animal, and Clinical Evidence.

BACKGROUND

Ceramides have garnered considerable attention as pro-aging bioactive lipids implicated in both metabolic dysfunction and musculoskeletal decline. Among these, C18:0 and C24:1 ceramides may play a role in the pathophysiology of sarcopenia, a key manifestation of age-related deterioration. However, their...

🗓️ 2026-05-01
📰 Publication: Journal Of Cachexia Sarcopenia And Muscle
Read MoreElevated Circulating Ceramides 18:0 and 24:1 as a Risk Factor for Sarcopenia: In Vitro, Animal, and Clinical Evidence.

Subscribe to the SCWD Newsletter

Stay Informed with the Latest Updates and Exclusive Insights!